MedTrace Logo

Impact of Body Weight and Weight Loss on Drug Bioavailability, Cardiovascular Risk Factors and Metabolic Biomarkers

NCT02386917 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-10-02

No results posted yet for this study

Summary

Drug bioavailability and disposition vary according to body weight and weight loss after bariatric surgery. This study evaluates the impact of body weight and weight loss on the pharmacokinetics of various probe drugs, and compares these effects in three groups of patients receiving either a gall bladder operation, gastric bypass or a very low calorie diet.

Conditions

Interventions

PROCEDURE

Gastric bypass

Weight loss surgery

BEHAVIORAL

Very low calorie diet

Non-surgical weight loss procedure

Sponsors & Collaborators

  • University of Oslo

    collaborator OTHER

  • AstraZeneca

    collaborator INDUSTRY

  • The Hospital of Vestfold

    lead OTHER

Principal Investigators

  • Jøran Hjelmesæth, Professor · The Hospital of Vestfold

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-18
Primary Completion
2019-06-30
Completion
2028-12-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02386917 on ClinicalTrials.gov